Psycheceutical Listed as 1 of 7 Psychedelic Stocks to Watch
PRESS ROOM
PSYCHECEUTICAL IN THE NEWS
Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption
Psychedelic Business Spotlight: Psycheceutical, Inc., Announces Exclusive License of Two Major Patents
PODCASTS
PRESS RELEASES
Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board.
Read More Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences
Vici Health Sciences CEO Anish Dhanarajan to join Psycheceutical as Research and Development Advisor.
Read More Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor
Famed entrepreneur excited about the company’s development of psychedelic pharmaceutical medicines to treat the widespread mental health crisis.
Read More Psycheceutical’s Chief Visionary Officer Zappy Zapolin Speaking at Legacy Investment Summit Alongside Entrepreneur Peter Diamandis
Psycheceutical Chief Visionary Officer, Zappy Zapolin, will be a featured presenter at the esteemed Legacy Investment Summit 2022, to be held at the Mandarin Oriental Hotel in Washington, D.C. on March 31…
Read More Psycheceutical Announces Agreement with Vici Health Sciences
Psycheceutical, Inc. has announced it has entered into a strategic agreement with Vici Health Sciences, known for providing pharmaceutical clients with tools to innovate and grow through new product development.…
Read More Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor
Esteemed neurosurgeon to participate in strategy, direction for development of novel psychedelic therapy innovations.
Read More Psycheceutical Completes Acquisition by Blue Water Ventures International
Psycheceutical, Inc., today announced the company has been fully acquired by Blue Water Ventures International, Inc. (OTCPK: BWVI).
Read More Psycheceutical Grows Scientific Advisory Board With Addition of Translational Research Expert, Zachary Clayton, PhD
Psycheceutical, Inc., today announced the addition of Zachary Clayton, PhD, to its scientific advisory board.
Read More Psycheceutical, Inc. Expands Executive Team With Announcement of New Advisory Board Appointments
Psycheceutical, Inc., today announced the growth of its esteemed board with two new appointments, Dr. Ronald Aung-Din and Dr. John Kutzko.
Read More Psycheceutical, Inc. Announces New Patents That Enable Psychedelic Compounds to Be Administered as Pharmaceutical Medicines
Psycheceutical, Inc., today announced its exclusive license within the entire psychedelic industry of two major patents that will significantly advance the medical application of psychedelic compounds.
Read More